Form 4: Neumora Therapeutics Director David Piacquad Reports Acquisition of Stock and Options

Director David Piacquad reported the acquisition of 20,100 shares of common stock and options to purchase 28,571 shares of common stock in Neumora Therapeutics.

Summary

• On June 13, 2024, David Piacquad, a director of Neumora Therapeutics, acquired 20,100 shares of common stock.
• These shares were received as restricted stock units (RSUs) that will vest on the earlier of June 13, 2025, or immediately before the next Annual Meeting following June 13, 2024.
• Piacquad also acquired options to purchase 28,571 shares of common stock at an exercise price of $9.95 per share.
• These options will vest on the earlier of June 13, 2025, or immediately before the next Annual Meeting following June 13, 2024.
• Following these transactions, Piacquad directly owns 20,100 shares of common stock and options to purchase 28,571 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by a director suggests confidence, but it's a routine transaction.

Positives

• The acquisition of stock and options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, such as directors and officers, trade their company's securities. These filings provide transparency into insider activity and can be used by investors to gauge management's sentiment about the company's prospects.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it signals confidence from a company director.

Key Dates